Ideas
Index likely trapped in range until expiry
Lee concluded that the recent extreme volatility was mainly a supply-demand dislocation from foreign derivative selling, retail buying, and ELS/DLS hedging rather than an internal Korean problem. Because the derivative overhang likely persists until the next futures/options expiry, he expects the Korean index to remain trapped/range-bound rather than break upward until then.
Rotate into Korean asset-value and value-up stocks
With the index range-bound, Lee expects a temporary rotation into previously neglected value-up/asset-value and traditional sectors. He notes similar moves in US industrials and Japanese traditional stocks and says Korean asset-rich, corporate-value names should see relative movement during a resting market.
Large marts may see relative strength
Lee cites large Korean mart/retail stocks as part of the neglected asset-value group; they rallied after authorities allowed 24-hour operation and delivery. He thinks this side can show relative movement while the broader market rests.
Buy Samsung, SK hynix on pullbacks
If the index is trapped, Lee does not expect Samsung Electronics or SK hynix to rise much. For investors without exposure, however, he sees pullbacks in these large semiconductor names as opportunities to accumulate.
February dividend stocks offer seasonal opportunity
For February, Lee flags companies with dividend-related events as a place to look for opportunities while the broad index is range-bound.
Focus North America-linked semiconductor equipment suppliers
In semiconductor equipment/materials, Lee limits his focus to companies tied to North America investment rather than the whole sector. He remains interested in this compressed group as a selective way to play the semiconductor supply chain.
Earnings-backed biotech names relatively resilient
Within biotech, Lee says the names holding up are those with actual earnings support, such as Celltrion and Hanmi Pharm, while speculative leaders have been volatile. He views these earnings-backed biotech names as relatively resilient.
Sam Chun Dang has different sales model
Lee points to Sam Chun Dang Pharm as a different kind of KOSDAQ biotech: instead of relying on a license-out story, it has already contracted to sell products. This gives it a more cash-flow-oriented, calmer profile that may fit the market's shifting preference.
Korean biotech needs new leader, avoid chasing
Lee has been reducing biotech exposure since late last year and recommended focusing on earnings in January. With existing leaders volatile and no new leader yet, he does not want to actively add to the Korean biotech sector until a credible license-out or cash-flow catalyst emerges.
ST Pharm revenue model worth watching
Lee highlights ST Pharm as another KOSDAQ biotech with a different profile because revenue is being recognized. Though he does not own it, he suggests it is worth watching if the market starts favoring sales/cash-flow-driven biotech over pure license-out stories.
Alteogen sold after noise emerged
Lee says he liquidated nearly all of his biotech trades made this year, including Alteogen, as soon as the noise emerged. He is therefore avoiding Alteogen rather than holding through the uncertainty.
This 815 Money Talk (815머니톡) video, published February 06, 2026,
features Lee Young-hoon
discussing EWY, Korean value-up/asset-value stocks, Korean large mart/retail sector, 005930.KS, 000660.KS, Korean dividend-related stocks, Korean semiconductor equipment/materials suppliers with North America investment exposure, 068270.KS, 128940.KS, 000250.KQ, Korean biotech sector, 237690.KQ, 196170.KQ.
11 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Young-hoon
· Tickers:
EWY,
Korean value-up/asset-value stocks,
Korean large mart/retail sector,
005930.KS,
000660.KS,
Korean dividend-related stocks,
Korean semiconductor equipment/materials suppliers with North America investment exposure,
068270.KS,
128940.KS,
000250.KQ,
Korean biotech sector,
237690.KQ,
196170.KQ